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Aims To determine waiting period-related morbidity, mortality, and adverse events in acute patients waiting for a perman-
ent pacemaker (PPM).
Methods
and results
A retrospective chart review of all PPM implantations in Region Zealand, Denmark, in 2009 was conducted. Patients
were excluded if they were discharged from the hospital during the waiting period or referred from the outpatient
department. Adverse events were tracked. Four hundred and eighty-seven PPM implantations were identified. Of
these, 259 patients (53.2%) required acute PPM implantation and waited a mean of 5.1 days from PPM indication
to implantation. A lack of implantation capacity was responsible for 4.5 of the waiting days. Twenty-nine patients
(11.2%) developed infection while waiting, primarily urinary tract infections. Thirteen patients (5.0%) suffered non-
sustained ventricular tachycardia, and eight patients (3.1%) suffered clinical cardiac arrest followed by successful
resuscitation. Three patients (1.2%) died during the waiting period before successful implantation. Forty-eight patients
(18.5%) received the sympathomimetic beta-adrenergic agent, isoprenaline, and seven patients (13.7%) had malignant
arrhythmias or cardiac arrest, reaching statistical significance (P, 0.05). Twenty-eight patients (10.8%) had a tempor-
ary transvenous-pacing catheter applied acutely.
Conclusions The patients awaited acute PPM implantations for a mean of 4.5 days because of capacity problems. Overall, 83
patients (32.0%) experienced at least one adverse event during the waiting period. The present study indicates
that a waiting period is dangerous as it is associated with an increased risk of adverse events. Acute PPMs should
be implanted with a 24-h pacemaker implantation service capacity.
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Introduction
An acute need for a pacemaker can arise and, with an ageing popu-
lation, there has been an increasing trend worldwide in cardiac
pacemaker implantation.1 Patients may have severe bradycardia,
third-degree atrioventricular block, or other life-threatening
ventricular arrhythmias, but symptoms are varied.2–5 Implantation
of a permanent pacemaker (PPM) without latency is not possible
for many patients because implantations are often not performed
at their local hospital or because there is limited implantation
capacity at those hospitals. Such is the case in Denmark, where
implantation capacity differs substantially by location. At some
centres, pacemaker implantation is performed 24 h a day. Other
centres, however, perform implantations only during the
daytime. This may lead to the more widespread use of intravenous
administration of sympathomimetic beta-adrenergic agents, such as
isoprenaline, temporary transvenous pacing (TTvP), and temporary
transcutaneous pacing (TTcP).2,6 –8 The patient journey from
symptom onset to PPM indication and implantation may take
several days.9 In Denmark, patients with another diagnoses such
as non-ST-myocardial infarction have a guaranteed waiting period
of ,72 h, and in some instances this may lead to increased
waiting periods for patients requiring acute PPM implantation as
procedures are performed in the same catheterization rooms.
While awaiting PPM implantation, some patients must remain hos-
pitalized at the referring hospital until a pacemaker implantation
can be performed at a regional pacemaker centre.
Delays in PPM implantation may result in an increase in compli-
cations,9,10 patient discomfort, and fear. Studies on the mortality-
and morbidity-related effects of a waiting period prior to PPM
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implantations are, however, limited. The current study describes
waiting period-related morbidity, mortality, and adverse events in
acute patients awaiting PPM implantation.
Methods
We performed a retrospective chart review of all PPM implantation
patients referred in 2009 to Roskilde Pacemaker Centre, Roskilde
Hospital, Region Zealand, Denmark. Patients were identified through
The Danish Pacemaker Register.11 In our study, acute patients were
defined as patients requiring hospitalization while waiting for a PPM
implantation. All patients discharged from the hospital during the
waiting period or referred from the outpatient departments were
excluded from the analysis. The patients were followed from hospital-
ization to the PPM implantation.
Data on gender, age, symptoms, date, and time of hospitalization and
PPM implantation were retrieved from the referring and implanting
hospitals. The indication for PPM was judged by the implanting phys-
ician. The waiting period was defined as the time from the initial
PPM indication until the implant procedure was performed. The
length of hospitalization and waiting period was calculated in days. A
waiting period because of comorbidities (such as medications, infec-
tions, or concomitant disease), which caused delays that were unre-
lated to logistic or capacity reasons, was calculated in days separately.
Adverse events during the waiting period were recorded and
defined as follows: infection: start of antibiotic treatment after hospital-
ization (patients already infected when hospitalized were excluded
unless they were without antibiotics in the waiting period) and any
further delay due to infection was recorded in days. Type of infection
was extracted from patient files, asystole: pause lasting .3.5 s; cardiac
arrest: need for cardiopulmonary resuscitation; malignant arrhythmias:
non-sustained or sustained ventricular tachycardia; syncope: sudden
fall with a loss of consciousness (not due to another recorded
adverse event); and death: dying during the waiting period.
Asystole and syncope were only noted once per patient, even
though the events may have occurred several times. The use of
TTvP and TTcP, as well as isoprenaline and infusion time, was
recorded.
Any observed difference was tested with Fisher’s exact test for
categorical data and Student’s t-test for continuous data. A two-sided
significance level of P, 0.05 was used.
Results
Four hundred and eighty-seven patients were referred to the
Roskilde Pacemaker Centre in 2009. Two hundred and
twenty-eight patients (46.8%) were excluded. Of those, 207
patients had an elective PPM procedure performed. Data on 12
patients could not be obtained through chart review, and nine
patients were excluded because they had a PPM implanted in
conjunction with other cardiac surgery. Overall, 259 patients
were referred for acute implantation and included in subsequent
analyses. Of these, three patients died before successful implant-
ation (Figure 1). Baseline characteristics are presented in Table 1.
The mean time from hospitalization to PPM implantation was 8.3
days (+6.7; range 0–29). After the patients were hospitalized,
there was a mean of 3.2 days (+5.4; range 0–27) before the indi-
cation for PPM implantation was detected, and there was a further
waiting period of 5.1 days (+3.8; range 0–19) before PPM
Figure 1 Flowchart of patients referred for permanent pacemaker implantation in Region Zealand in 2009.
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implantation. Comorbidities at the time of PPM indication delayed
implantation by a mean of 0.6 days (+2.1; range 0–14). Therefore,
the mean waiting period of 4.5 days (+3.6; range 0–15) was
primarily associated with a lack of implantation capacity. No differ-
ences in the waiting period were found between referring hospitals
(P ¼ 0.45).
Isoprenaline was administered intravenously to 18.5% of patients
while they waited. The mean infusion time was 1.7 days (+2.4;
range 0–13). The TTvP was applied during the waiting period to
28 patients (10.8%), and 18 patients (6.9%) had TTcP applied but
not necessarily activated (Table 2).
There were 111 preoperative adverse events recorded in 83
patients (32.0%). These are presented in Table 3. Patients with a
waiting period of .1 day experienced an adverse event more
often than patients with a waiting period equal to or ,1 day
(36.7 vs. 20.4%), P, 0.05 (Figure 2). The proportion of patients
who acquired an infection was higher after 6 days compared
with waiting periods ≤ 6 days (22.9 vs. 4.2%), P, 0.01. Patients
with a third-degree atrioventricular (AV)-block more often had a
severe adverse event (syncope, cardiac arrest, VT, death) (17.1
vs. 7.4%), P, 0.01. By including patients with a second-degree
AV-block we still found a difference (14.0 vs. 8.7), but could not
reach statistical significance, P ¼ 0.19. A reported syncope when
admitted to hospital did not predict any differences in same
severe events (11.2 vs. 10.5%), P ¼ 1.0.
Non-sustained ventricular tachycardia and cardiac arrest were
seen with a higher incidence in patients receiving or who had
received isoprenaline during the waiting period (13.7 vs. 3.9%),
P, 0.05 (Figure 3). Infusion time was not statistically associated
with these adverse events (infusion time ≤1 day vs. .1 day),
P ¼ 0.25; and (infusion time ≤2 days vs. .2 days), P ¼ 0.24.
Two out of 30 patients (6.6%) suffered complications related to
the TTvP system (lead displacements), and in one of these cases,
the patient suffered cardiac arrest due to pace failure. Both patients
had their TTvP replaced immediately.
Three patients died before successful PPM implantation:
(1) An 82-year-old woman with diabetes mellitus but who was
otherwise healthy pre-admission was hospitalized after
syncope. After 7 days, she showed an intermittent third-
degree AV-block and was referred to the local pacemaker
centre. There were no available times for implants within
the following 8 days. Three days after PPM indication, the
patient was diagnosed with non-focused infection. The
patient was treated with intravenous antibiotics, but after
Table 1 Baseline characteristics of acute permanent
pacemaker implantations
Number of acute PPM implantations 259
Age (years) 78 (+10.7; range 37–98)
Male (%) 46
Indications (%)
Third-degree AV-block (n) 39.9 (108)
Sick sinus syndrome (n) 27.8 (72)
Atrial fibrillation and bradycardia (n) 15.1 (39)
Second-degree AV-block (n) 9.7 (25)
Tachy-bradycardia syndrome (n) 7.3 (19)
Other (n) 3.1 (8)
Symptoms at time of hospitalization
(%)
Syncope (n) 47.1 (122)
Dizziness (n) 27.8 (72)
Dyspnoea (n) 17.4 (45)
Other (n) 13.1 (34)
None (n) 10.8 (28)
Nausea (n) 2.3 (6)
Table 2 Length of hospital stay, waiting period, and
treatment of acute permanent pacemaker
implantations
Time from hospitalisation to PPM
implantation (days)
8.3 (+6.7; range 0–29)
Time from hospitalisation to PPM
indication (days)
3.2 (+5.4; range 0–27)
Waiting period from PPM indication to
implantation (days)
5.1 (+3.8; range 0–19)
Waiting period due to co-morbidities
(days)
0.6 (+2.1; range 0–14)
Waiting period due to infection during
the waiting period (days)
2.0 (+2.0; range 0–12)
Waiting period due to lack of capacity
(days)
4.5 (+3.6; range 0–15
Use of a isoprenaline (%) 18.5
Infusion time (days) 1.7 (+2.4; range 0–13)
Use of TTvP (%) 10.8
Use of TTcP (%) 6.9
TTvP, temporary transvenous pacemaker; TTcP, temporary transcutaneous
pacemaker.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Adverse events during the permanent
pacemaker-implantation waiting period
Times
registered
Observed in
patients
Overall adverse events 111 83
Infections (n) 29 29
Urinary tract (%) 62.2 –
Unknown (%) 24.1 –
Pneumonia (%) 13.8 –
Syncope (n) – 6
Asystole (n) – 53
Non-sustained ventricular
tachycardia
14 13
Cardiac arrest 9 8
Death 3 3
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2 days, she entered a diabetic coma, suffered circulatory col-
lapse, and died.
(2) A 91-year-old man was hospitalized with dizziness and third-
degree AV-block and was diagnosed with non-ST-elevation
myocardial infarction. The patient was referred for PPM im-
plantation 3 days later. After 6 days without PPM implantation,
the patient developed an infection, and implantation was post-
poned temporarily. Two days after he finished antibiotic treat-
ment, the patient experienced two cardiac arrest events, both
followed by successful resuscitation. After the second resusci-
tation, he exhibited signs of cerebral anoxia, and further treat-
ment was not attempted. The patient died 7 days later.
(3) A 90-year-old woman was hospitalized while unconscious and
hypotensive with a third-degree AV-block and bradycardia. An
infusion of isoprenaline had a positive effect, and the patient
was referred to a local pacemaker centre. The next day, she
developed severe bradycardia, despite the use of isoprenaline
infusions. She was transferred to a local PPM centre, and TTcP
was applied. Upon arrival, the patient was unconscious, and
following PPM implantation, she suffered several AV-blocks
and cardiac arrest. Fluoroscopy showed no ventricular con-
traction and no effect of transcutaneous pacing. Further resus-
citation was not attempted.
Discussion
The inability to meet the acute need for PPM implants because of a
lack of adequate implantation capacity may be dangerous and have
severe consequences. In this study, we found that an increased
waiting period was associated with increased morbidity and
mortality. The waiting period of 4.5 days was caused by a lack of
implantation capacity. Comorbidities presenting at the time of
PPM indication delayed implantation further, but only by 0.6
days. This rather small delay may result from the fact that patients
with severe comorbidities might not be referred for a PPM
implantation procedure at all.12 In addition to this waiting period,
patients were hospitalized for a mean 3.2 days before a PPM indi-
cation was established. Thus, their overall hospital stays were pro-
longed to 8.9 days. These results are consistent with what other
studies have found.13 We were not able to report if a waiting
period from PPM indication to referral exists, but in practice we
think this would be of no significance. All patients were in
general and to our knowledge electrocardiogram -monitored
while waiting.
A prolonged waiting period is dangerous, as evidenced by the
increased number of patients suffering an adverse event when
the waiting period exceeded .1 day. Some patients experienced
a series of adverse events. We found that third-degree AV-block
was predictive as compared with the risk of severe adverse
events (cardiac arrest, death, syncope, VT), and this emphasizes
that these patients should be transferred to hospitals with TTvP
Figure 2 Percentage of patients with at least one adverse event (infection, non-sustained ventricular tachycardia, cardiac arrest, syncope,
asystole, death) as a function of the waiting period, P, 0.05 (.1 day vs. ≤1 day).
Figure 3 Percentage of patients with at least one adverse event
(cardiac arrest or non-sustained ventricular tachycardia) distribu-
ted in two groups. Patients who received isoprenaline vs. patients
who did not receive isoprenaline (P, 0.05).
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implantation capacity. No differences in the number of events were
found when admitted with or without syncope.
Infections had a significantly higher prevalence after 6 days but
were not found to delay implantation much further, and patients
were only seldom required to reschedule an operation. The
minimal impact that this played in delaying implantation may be
due to the expedient use of antibiotics. Most common were
urinary tract infections and in the elderly hospitalized patient popu-
lation they will correlate with the length of hospital stay. We
cannot tell whether a few patients were infected before hospital-
ization, but we believe that the majority of infections would have
been avoided if not hospitalized. Only one infection was recorded
within the first 24 h.
We describe three deaths that might have been avoided if PPM
implantation were possible, although we have some concerns
regarding their deaths. All three patients were old with comorbid-
ities that in part could influence the outcome with or without a
pacemaker implant. In the first case, the patient may have suffered
from diabetic coma due to infection after a pacemaker implant. A
reduced or no waiting period would nevertheless has diminished
her risk. In the second case, the patient suffers from ischaemic
heart disease and develops a secondary need of PPM. Even
though implanted immediately he might still have had the cardiac
arrest a few days later after being discharged. Antibiotic treatment
could have been avoided. To our knowledge, no coronary angiog-
raphy was performed in this patient before death and it may influ-
ence on the outcome. Implantation of a TTvP would require
transfer to local PPM implantation centre, and this could have
saved his life, but was not done. The third patient was treated
with isoprenaline instead of temporary pacing despite third-degree
AV-block and circulatory collapse. Isoprenaline has an immediate
effect on the patient and it is conceivable that she would have sur-
vived if instead transferred with the aim of PPM or TTvP
implantation.
When PPM implantation is needed but cannot be provided
immediately because of a lack of sufficient implantation capacity,
isoprenaline or TTvP can be used as an alternative for patients suf-
fering from severe bradycardia or having asystolia.2,6,7,14 In the
present study, isoprenaline was used far more than TTvP. This
occurrence is not surprising, as TTvP systems in the Region of
Zealand are only implanted at the same regional centre that
implants PPMs. Therefore, if isoprenaline administration was
deemed insufficient, patients would have to be transferred to the
regional pacemaker centre on an acute basis, often with bridging
use of TTcP.8 Patient transports do always, but especially when
performed outside daytime, require great resources from personal,
equipment, logistics, etc. This might explain the more widespread
use of isoprenaline instead of transfer in the first place.
Even though referred to urgent PPM implantation a high propor-
tion of patients had a clinical cardiac arrest. We recorded nine
cardiac arrests in eight patients (3.1%), in two of these patients it
happened due to displacement of a temporary pacing catheter.
Three other patients of the remaining six were treated with
isoprenaline before the event. In fact, a significantly higher propor-
tion of patients had malignant arrhythmias and suffered cardiac
arrest after receiving isoprenaline, but we could not relate infusion
time to the events. It was not possible to estimate the total infused
dose of isoprenaline, and dosing may be the explanation for the
observed elevation in the frequency of cardiac complications.
However, there were only two complications related to TTvP
implantations, and in both cases the patient experienced lead
displacement. This emphasizes that TTvP systems should be
preferred as an acute intervention, compared with the use of
isoprenaline, and should be implanted when possible. If not,
transfer to a regional pacemaker centre should be considered.
Even though isoprenaline may increase the risk of an adverse
event, it is still the drug of choice when patients are transferred
to PPM and TTvP implantation centres.
Increasing the capacity for PPM implantation to a 24-h service
could not only reduce the number of adverse events and diminish
the use of antibiotic treatments, isoprenaline, and TTvP implanta-
tions, but also potentially reduce the overall costs of hospitaliza-
tion of 259 patients by up to 4.5 days each year.
In conclusion, a waiting period between PPM indication and
implantation is dangerous as it is associated with an increased
risk of adverse events, such as infections, syncope, asystole, malig-
nant arrhythmias, cardiac arrest, and death. Patients receiving
isoprenaline had a higher incidence of malignant arrhythmias and
cardiac arrest: TTvP should be the first choice because of the
reduced frequency of resulting complications. The need for PPM
often arises on an acute basis, and a 24-h PPM implantation
service could reduce the rate of adverse events and diminish the
use of antibiotic treatments, isoprenaline, and TTvP implantations.
This study has limitations as we performed a multi-centre retro-
spective chart review of 487 patients but only 259 patients were
referred for acute implantation and included. We cannot tell if
waiting time outside hospital may be even more dangerous. The
results are in part limited to this type of health care system,
where TTvP implants not always are possible which gives a
frequent use of isoprenaline, that in part will explain some of the
adverse events. To improve the significance of the results a
larger cohort should be studied over a longer period in a
prospective matter.
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